News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Iran Denies Direct Talks; Oil Price Back Above $100; Nasdaq 100 Rule Change May Open Door for SpaceX (March 31, 2026)2Bitcoin data points to ‘rare’ trading setup for relief rally to $71K3Iran's Potential Blockade of the Strait of Hormuz: Approaching April 6 and Growing Market Anxiety
Mike Novogratz Says Ripple Is Now an Institution, The XRP Army Is Real. Here’s why
TimesTabloid·2026/03/19 16:10
How Oklo's Approach to Nuclear Power Enhances Stability During Global Political Uncertainty
101 finance·2026/03/19 16:10
Can Carter's strong retail performance counterbalance tariff challenges in 2026?
101 finance·2026/03/19 16:10
Lumentum's robust performance in OCS and CPO signals wider market demand: What does the future hold?
101 finance·2026/03/19 16:10
Carnival Benefits From Robust Onboard Purchases: A Catalyst for Yield?
101 finance·2026/03/19 16:10
Semtech’s April 1.6T ACC Delivery May Trigger a 30% Surge—However, Delay Could Destroy the Valuation
101 finance·2026/03/19 16:10
Arcos Dorados (ARCO) Fourth Quarter 2025 Earnings Call Transcript
101 finance·2026/03/19 16:06
Reasons to Keep Avanos Medical Shares in Your Investment Portfolio at This Time
101 finance·2026/03/19 16:03
USD/JPY declines despite the Fed maintaining a hawkish stance
101 finance·2026/03/19 16:03
Flash
13:16
Eli Lilly plans to acquire biotechnology company Centessa for up to $7.8 billions.Luo Tonghui March 31｜Eli Lilly announced that it has reached a definitive agreement to acquire Centessa Pharmaceuticals, a clinical-stage biotechnology company, with a total transaction value of up to $7.8 billion. Eli Lilly will acquire Centessa shares for $38 in cash per share, representing a 40.5% premium over its volume-weighted average price on the 30th; if regulatory milestones are achieved in the future, each share may receive up to an additional $9. This acquisition will grant Eli Lilly ownership of Centessa's orexin receptor 2 (OX2R) agonist product line, including cleminorexton, which is considered a potential best-in-class therapy for sleep-wake disorders such as narcolepsy type 1 and type 2 as well as idiopathic hypersomnia. The portfolio also includes several early-stage candidate drugs with potential in the broader neurological and neuropsychiatric disease fields.
13:07
Galaxy Digital announces that its GalaxyOne platform has launched SOL staking functionalityJinse Finance reported that on March 31, the Nasdaq-listed crypto financial services group Galaxy Digital announced that its fintech platform GalaxyOne has launched SOL staking functionality. This service is open to eligible customers in more than 40 states and regions in the United States, and all SOL staked on GalaxyOne will be delegated to the Galaxy Digital validator.
13:07
Blockchain infrastructure platform Uniblock completes $5.2 million new financing with participation from SBI and othersPANews reported on March 31 that, according to official sources, blockchain infrastructure platform Uniblock has announced the completion of a new $5.2 million funding round, bringing its total funding to $7.5 million. Investors included SBI, AllianceDAO, CoinSwitch, Blockchain Founders Fund, Hustle Fund, AAF Management, NGC Ventures, Alchemy, MoonPay and others. The funds from this round will be used for platform expansion, market development, and team building. According to the introduction, Uniblock connects to over 300 blockchains and 55 data partners through a single API, providing services such as automatic routing, failover, and data standardization. Currently, the platform is used by 3,000 projects and 4,000 developers, with clients including Plume Network, Stellar, Hypernative, Oku Trade, nReach, and Apechain. Uniblock has also launched AI-native development tools, including the MCP server, llms.txt documentation, and Agent Skills, supporting AI coding environments such as Claude, Codex, and Cursor.
News